

## ORAL AMELANOTIC MELANOMA

A.O. Adisa<sup>1</sup>, W.O. Olawole<sup>2</sup> and O.F. Sigbeku<sup>1</sup>

1. Department of Oral Pathology, University College Hospital, Ibadan
2. Department of Oral and Maxillofacial Surgery, University College Hospital, Ibadan

*Correspondence:***Dr. A.O. Adisa**

Dept. of Oral Pathology

University College Hospital

Ibadan

e-mail: perakin80@hotmail.com

**ABSTRACT**

Malignant melanomas of the mucosal regions of the head and neck are extremely rare neoplasms accounting for less than 1% of all melanomas. Approximately half of all head and neck melanomas occur in the oral cavity. Less than 2% of all melanomas lack pigmentation, in the oral mucosa however, up to 75% of cases are amelanotic.

No etiologic factors or risk factors have been recognized for oral melanomas. Some authors have suggested that oral habits and self-medication may be of etiological significance. Oral melanoma is rare but it is relatively frequent in countries like Japan, Uganda, and India. It is rarely identified under the age of 20 years. In Australia where cutaneous melanomas are relatively common primary melanoma of the oral mucosa is rare.

The surface architecture of oral melanomas ranges from macular to ulcerated and nodular. The lesion is said to be asymptomatic in the early stages but may become ulcerated and painful in advanced lesions.

The diagnosis of amelanotic melanoma is more difficult than that of pigmented lesions. The neoplasm consists of spindle-shaped cells with many mitotic figures and no cytoplasmic melanin pigmentation. Immunohistochemistry using S-100, HMB-45, Melan-A and MART-1 will help in establishing the correct diagnosis.

Radical surgery with ample margins and adjuvant chemotherapy are appropriate management protocol for malignant melanoma.

Oral melanoma is associated with poor prognosis but its amelanotic variant has even worse prognosis because it exhibits a more aggressive biology and because of difficulty in diagnosis which leads to delayed treatment.

**Keywords:** amelanotic melanoma, oral cavity

**INTRODUCTION**

Malignant melanomas of the mucosal regions of the head and neck are extremely rare neoplasms accounting for less than 1% of all melanomas<sup>1</sup>. Approximately half of all head and neck melanomas occur in the oral cavity, followed by the nasal cavity (44%) and sinuses (8%)<sup>2</sup>. The most frequent sites in the oral cavity are the hard palate (more than 40%) and the gingiva<sup>2</sup>. Melanomas arise from the uninhibited proliferation of melanocytes found in the basal layer of the oral mucous membranes<sup>3</sup>. The clinical presentation of this neoplasm varies widely, from a typically pigmented macular or nodular lesion, to a non-pigmented neoplasm that may be solitary or multiple, primary or metastatic<sup>4</sup>. Less than 2% of all melanomas lack pigmentation, in the oral mucosa however, up to 75% of cases are amelanotic<sup>5,6,7</sup>.

In contrast to cutaneous melanomas, which may present with a horizontal or vertical growth pattern, oral melanomas usually present typically with vertical growth, thus spreading to contiguous sites early<sup>8</sup>. The prognosis for oral melanomas is poor, with an overall 5-year survival rate of 15%<sup>8</sup>.

**Etiology**

In oral mucosa, melanocytes are located along the tips and peripheries of the rete pegs. No etiologic factors have been recognized for oral melanomas. Risk factors have also remained obscure. There appears to be no geographic variations and only minor ethnic and gender differences<sup>9</sup>. Some oral melanomas are believed to originate from junctional nevis, others are thought to arise from pre-existing Hutchinson's malignant lentigo<sup>10</sup>.

Some authors have suggested that oral habits and self-medication may be of etiological significance in some Indian and African groups<sup>11</sup>. According to Tanaka *et al*<sup>12</sup>, the biological behavior of melanoma may be related to the expression of the proteins Rb, pRb2/p130, p53 and p16, which may be helpful in predicting the manifestation of this neoplasm, including the melanin content.

### **Epidemiology**

Oral melanoma is rare but it is relatively frequent in countries like Japan, Uganda, and India<sup>13</sup>. Oral melanoma is a lesion of adulthood, rarely identified under the age of 20 years. In a study, the highest incidence of malignant melanoma was reported in the fifth to eight decades of life<sup>14</sup>. Hicks and Flaitz<sup>8</sup> in a review of oral malignant melanoma showed a male predilection and an age range of 22 to 83 years, with a mean age of 56 years. There is a higher incidence of melanoma of the oral mucosa among Japanese than Caucasians<sup>15</sup>. According to an African research, 1.7% of all melanomas in Sudan occurred in the oropharynx and 0.9% of the melanomas in Nigeria originated within the oral cavity<sup>11</sup>. In Australia where cutaneous melanomas are relatively common primary melanoma of the oral mucosa is rare<sup>14</sup>.

### **Clinical features**

The surface architecture of oral melanomas ranges from macular to ulcerated and nodular<sup>9</sup>. Indeed clinically, the tumors are classified into five types: I - pigmented nodular, II - non-pigmented nodular, III - pigmented macular, IV - pigmented mixed, and V - non-pigmented mixed type<sup>16</sup>. The lesion is said to be asymptomatic in the early stages but may become ulcerated and painful in advanced lesions<sup>17</sup>.

### **Histology**

The diagnosis of amelanotic melanoma is more difficult than that of pigmented lesions<sup>18</sup>. Histological description of a specimen by Notani *et al*<sup>9</sup> showed that the neoplasm consisted of spindle-shaped cells with many mitotic figures and there was no cytoplasmic melanin pigmentation. These malignant cells possess considerable pleomorphism, with large, irregular hyperchromatic nuclei and prominent nucleoli<sup>8</sup>. Others have reported pleomorphic epithelioid cells with bizarre nuclei, large cherry-red nucleoli, occasional nuclear pseudo-inclusions and variable amounts of dusty cytoplasmic pigment<sup>20</sup>.

### **Diagnosis**

Lesions that are suspected to be melanomas should be assessed both histologically and by immunohistochemistry, which are helpful in the diagnosis of amelanotic melanoma and only slightly pigmented

melanoma<sup>21,22</sup>. The immunohistochemical techniques using S-100, HMB-45, Melan-A and MART-1 will help in establishing the correct diagnosis<sup>21</sup>.

### **Treatment**

Notani *et al*<sup>9</sup> suggests a combination of radical surgery with ample margins and adjuvant chemotherapy as an appropriate management protocol for malignant melanoma. Many chemotherapy agents have been used for malignant melanomas but dacarbazine was reported to have the best response rate of about 20% as a single agent<sup>23</sup>. The addition of the immunomodulator, OK-432, injected around the neoplasm has been advocated for treatment and prolonging survival periods in oral lesions<sup>24</sup>.

Radiotherapy has been considered to have only a palliative role and on its own was reported to be ineffective since the lesion is not very radiosensitive<sup>25</sup>. On the other hand, Tanaka *et al*<sup>16</sup> found radiotherapy to be more successful than surgery for oral melanoma. The treatment of amelanotic melanoma does not differ in anyway from the pigmented neoplasm.

### **Prognosis**

Lymphatic metastasis at the time of diagnosis seems to be the best prognostic factor for oral melanoma<sup>26</sup>. Rogers and Gibson<sup>22</sup> reported that half of all patients with oral melanoma had regional lymph node metastases and 20% had disseminated melanomas at initial assessment. The prognosis of amelanotic melanoma tends to be poorer<sup>18</sup>. Indeed, Nandapalan *et al*<sup>25</sup> in a review of 257 mucosal melanomas of the head and neck region reported that amelanotic melanomas had a 20% survival at 3 years, whereas pigmented melanoma had a 58% survival at 3 years. This has resulted in part from delays in determining a definitive diagnosis and initiating treatment. Poor prognosis may also be due to the fact that amelanotic lesions tend to exhibit vertical growth pattern while the pigmented lesion showed a more radial growth pattern. Ohashi *et al*<sup>21</sup> reported that of eight oral melanomas without a radial growth pattern, only one presented as a melanotic type, whereas 18 of 27 with a radial growth patterns were melanotic. Vertical growth will lead to early involvement of contiguous structures and worsen the overall outcome. Milton also drew attention to the fact that fast-growing melanomas often have relatively less pigment than slow-growing ones<sup>27</sup>.

### **CONCLUSION**

Oral melanoma is a relatively rare neoplasm associated with poor prognosis but its amelanotic variant has even worse prognosis because it exhibits a more aggressive

biology and because of difficulty in diagnosis which leads to delayed treatment.

## REFERENCES

1. **Demo PG**, Fasolis M, Maggiore GM, *et al.* Oral mucosal melanoma: a series of case reports. *J Craniomaxillofac Surg* 2004; 32:251–257.
2. **Ortega KL**, Araújo NSD, Bitu SF, *et al.* Primary malignant melanoma of the oral cavity: a case report. *Int. J Dermatology* 2004;43:750–752.
3. **Patton LL**, Brahim JS, Baker AR. Metastatic malignant melanoma of the oral cavity. A retrospective study. *Oral Surg Oral Med Oral Pathol* 1994;78:51-56.
4. **Batsakis JG**. Pathology of tumors of the oral cavity. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD, eds. *Comprehensive management of head and neck tumors*. Philadelphia: W B Saunders, 1987:499-502.
5. **Trodahl JN**, Sprague WG. Benign and malignant melanocytic lesions of the oral mucosa. An analysis of 135 cases. *Cancer* 1970; 25: 812–823.
6. **Anneroth G**, Carlson GO, Eneroth CM, Moberger G. Primary melanoma in the oral mucosal membrane. *Swed Dent J* 1973; 66: 27–37.
7. **Berthelsen AP**, Andresen T, Jensen SS, Hansen H. Melanomas of the mucosa in the oral cavity and the upper respiratory passages. *Cancer* 1984; 54: 907–912.
8. **Hicks MJ**, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. *Oral Oncol*. 2000; 36:152–169.
9. **Silverman S**. Oral cancer. 5<sup>th</sup> ed. BC Decker Inc: Hamilton, London; 2003; 155-157.
10. **Neville BW**, Damm D, Allenc R, Bouquot JE. Oral and maxillofacial pathology. 2<sup>nd</sup> ed. W.B Saunders: Philadelphia; 2002; 334,376-380.
11. **Goubran GF**, Adekeye EO, Edwards MB. Melanoma of the face and mouth in Nigeria: A review and comment on three cases. *Int J Oral Surg* 1978;7: 453-462.
12. **Tanaka N**, Odajima T, Mimura M, Ogi K, Dehari H, Kimijima Y, Kohama G. Expression of Rb, pRb2/p130, p53, and p16 proteins in malignant melanoma of oral mucosa. *Oral Oncol* 2001; 37(3):308-314.
13. **Steidler NE**, Reade PC, Radden BG. Malignant melanoma of the oral mucosa. *J Oral Maxillofac Surg* 1984;42:333-336.
14. **van der Waal RI**, Snow GB, Karim AB, *et al.* Primary malignant melanoma of the oral cavity: a review of eight cases. *Br Dent J* 1994 Mar 5;176(5):185-186.
15. **Takagi M**, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan; with special reference to mucosal melanomas. *Cancer* 1974; 34: 359–370.
16. **Tanaka N**, Amagasa T, Iwaki H *et al.* Oral malignant melanoma in Japan. *Oral Surg Oral Med Oral Pathol* 1994; 78: 81–90.
17. **Jackson D**, Simpson HE. Primary malignant melanoma of the oral cavity. *Oral Surg Oral Med Oral Pathol* 1975 Apr;39(4):553-559.
18. **Irving MA**. Amelanotic melanoma; an analysis of 77 patients. *Curr Surg* 1981; 38: 151–155.
19. **Notani K**, Shindoh M, Yamazaki Y, Nakamura H, Watanabe M, Kogoh T, Ferguson M M, Fukuda H. Amelanotic malignant melanomas of the oral mucosa. *Brit J of Oral and Maxillofacial Surgery* (2002) 40, 195–200
20. **Patrick M**, Timothy S. Lymph Node Melanosis in a Patient With Metastatic Melanoma of Unknown Primary Arch Pathol Lab Med. 2009;133:1332–1334
21. **Ohashi K**, Kasuga T, Tanaka N, Enomoto S, Horiuchi J, Okada N. Malignant melanoma of the oral cavity: heterogeneity of pathological and clinical features. *Virchows Arch A*, 1992; 420: 43–50.
22. **Rogers RS**, Gibson LE. Mucosal, genital, and unusual clinical variants of melanoma. *Mayo Clin Proc* 1997; 72: 362–366.
23. **Balch CM**, Houghton A, Peters L. Cutaneous melanoma. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. *Cancer: Principle & Practice of Oncology*, 3rd edn. Philadelphia: Lippincott, 1989: 1499–1542.
24. **Kirkwood JM**, Wilson J, Whiteside TL, Donnelly S, Herberman RB. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. *Cancer Immunol Immunother* 1997; 44: 137–149.
25. **Nandapalan V**, Roland NJ, Helliwell TR, Williams EM, Hamilton JW, Jones AS. Mucosal melanoma of the head and neck. *Clin Otolaryngol Allied Sci* 1998; 23: 107–116.
26. **Ardekian L**, Rosen DJ, Peled M, Rachmiel A, Mach- tei EE, el Naaj IA, Laufer D. Primary gingival malignant melanoma. Report of 3 cases. *J Periodontol* 2000;71(1):117-120.
27. **Milton GW**. Melanoma of the nose and mouth. In: Milton GW, ed. *Malignant melanoma of the skin and mucous membrane*. Edinburgh: Churchill Livingstone, 1977; 157–164.